Euglycemic diabetic ketoacidosis (euDKA) is an acute, life-threatening metabolic emergency. It has been associated with several factors, including sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Fewer cases of euDKA have been associated with glucagon-like peptide 1 receptor agonists, and this we hypothesize might be the result of underreporting. With increasing use of these agents in the treatment of diabetes, perhaps more cases of euDKA will be encountered in the clinics, urgent care, emergency departments, and inpatient settings. Hence, a high index of suspicion is key for early diagnosis and appropriate management. Here, we present a case report of euDKA associated with semaglutide.
No takes yet. Share an insight, caveat, or question.
Kanu et al. (2024) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: